218 related articles for article (PubMed ID: 31859626)
1. [Dermatomyositis: new antibody, new classification].
Bolko L; Gitiaux C; Allenbach Y
Med Sci (Paris); 2019 Nov; 35 Hors série n° 2():18-23. PubMed ID: 31859626
[TBL] [Abstract][Full Text] [Related]
2. [Dermatomyositis and Autoantibodies].
Fujimoto M
Brain Nerve; 2018 Apr; 70(4):427-438. PubMed ID: 29632290
[TBL] [Abstract][Full Text] [Related]
3. Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets.
Merlo G; Clapasson A; Cozzani E; Sanna L; Pesce G; Bagnasco M; Burlando M; Parodi A
Arch Dermatol Res; 2017 Mar; 309(2):87-95. PubMed ID: 27928683
[TBL] [Abstract][Full Text] [Related]
4. Dermatomyositis Clinical and Pathological Phenotypes Associated with Myositis-Specific Autoantibodies.
Wolstencroft PW; Fiorentino DF
Curr Rheumatol Rep; 2018 Apr; 20(5):28. PubMed ID: 29637414
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis.
Tartar DM; Chung L; Fiorentino DF
Clin Dermatol; 2018; 36(4):508-524. PubMed ID: 30047434
[TBL] [Abstract][Full Text] [Related]
6. [Retrospective analysis of anti-TIF1gamma, anti-NXP2 and anti-SAE1/2 antibodies carriers at Bordeaux university hospital from November 2014 to February 2017].
Victor J; Zanardo L; Héron-Mermin D; Poursac N; Solé G; Bordes C; Duffau P
Rev Med Interne; 2019 Feb; 40(2):70-81. PubMed ID: 30527961
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in dermatomyositis-specific autoantibodies.
Fujimoto M; Watanabe R; Ishitsuka Y; Okiyama N
Curr Opin Rheumatol; 2016 Nov; 28(6):636-44. PubMed ID: 27533321
[TBL] [Abstract][Full Text] [Related]
8. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan.
Iwata N; Nakaseko H; Kohagura T; Yasuoka R; Abe N; Kawabe S; Sugiura S; Muro Y
Mod Rheumatol; 2019 Sep; 29(5):802-807. PubMed ID: 30092736
[No Abstract] [Full Text] [Related]
9. Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease.
Li L; Wang H; Wang Q; Wu C; Liu C; Zhang Y; Cheng L; Zeng X; Zhang F; Li Y
J Neurol Sci; 2019 Feb; 397():123-128. PubMed ID: 30616054
[TBL] [Abstract][Full Text] [Related]
10. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America.
Mamyrova G; Kishi T; Shi M; Targoff IN; Huber AM; Curiel RV; Miller FW; Rider LG;
Rheumatology (Oxford); 2021 Apr; 60(4):1839-1849. PubMed ID: 33140079
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies in children with juvenile dermatomyositis: A single centre experience from North-West India.
Hussain A; Rawat A; Jindal AK; Gupta A; Singh S
Rheumatol Int; 2017 May; 37(5):807-812. PubMed ID: 28331982
[TBL] [Abstract][Full Text] [Related]
12. Distinct tissue injury patterns in juvenile dermatomyositis auto-antibody subgroups.
Nguyen M; Do V; Yell PC; Jo C; Liu J; Burns DK; Wright T; Cai C
Acta Neuropathol Commun; 2020 Aug; 8(1):125. PubMed ID: 32758284
[TBL] [Abstract][Full Text] [Related]
13. Myositis autoantibodies.
Casciola-Rosen L; Mammen AL
Curr Opin Rheumatol; 2012 Nov; 24(6):602-8. PubMed ID: 22955022
[TBL] [Abstract][Full Text] [Related]
14. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
Ye Y; Fu Q; Wang R; Guo Q; Bao C
J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
[TBL] [Abstract][Full Text] [Related]
15. Autoantibody profiles in patients' sera associated with distribution patterns of dermatomyositis skin symptoms.
Ogawa-Momohara M; Kinoshita F; Muro Y; Kobayashi Y; Takeichi T; Akiyama M
J Am Acad Dermatol; 2021 Jun; 84(6):1720-1722. PubMed ID: 33867178
[No Abstract] [Full Text] [Related]
16. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis.
Hoshino K; Muro Y; Sugiura K; Tomita Y; Nakashima R; Mimori T
Rheumatology (Oxford); 2010 Sep; 49(9):1726-33. PubMed ID: 20501546
[TBL] [Abstract][Full Text] [Related]
17. Interstitial lung disease in an adult patient with dermatomyositis and anti-NXP2 autoantibody.
Gossez M; Levesque M; Khouatra C; Cottin V; Garnier L; Fabien N
Eur Respir Rev; 2015 Jun; 24(136):370-2. PubMed ID: 26028648
[TBL] [Abstract][Full Text] [Related]
18. Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review.
Yeung TW; Cheong KN; Lau YL; Tse KN
Pediatr Rheumatol Online J; 2021 Jun; 19(1):103. PubMed ID: 34193210
[TBL] [Abstract][Full Text] [Related]
19. Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort.
Bodoki L; Nagy-Vincze M; Griger Z; Betteridge Z; Szöllősi L; Dankó K
Autoimmun Rev; 2014 Dec; 13(12):1211-9. PubMed ID: 25182203
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics of four myositis-specific autoantibodies with regulatory-approved testing in Japan: A Japanese multi-centre adult myositis patients' cohort.
Ueda-Hayakawa I; Fujimoto M; Sato S; Murakami A; Kawakami A; Mishima M; Seishima M; Suda T; Takehara K; Mimori T; Kuwana M
J Dermatol Sci; 2021 Jul; 103(1):53-56. PubMed ID: 34088590
[No Abstract] [Full Text] [Related]
[Next] [New Search]